Neumentum, Inc. Executive Chairman, Joseph Pergolizzi, Jr., M.D. and Chief Scientific Officer, Robert Raffa, Ph.D. To Present at 2019 Pain Summit in Philadelphia, PA

by Neumentum Pharmaceuticals | Nov 14, 2019 | In The Media, Press Releases

PALO ALTO, Calif., November 14, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Joseph Pergolizzi, Jr., M.D. and Robert Raffa, Ph.D., will both present keynote speeches at the...

Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at 2019 BIO Investor Forum in San Francisco, CA

by Neumentum Pharmaceuticals | Oct 17, 2019 | In The Media, Press Releases

PALO ALTO, Calif., October 17, 2019 – Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2019 BIO Investor Forum being held October...

Neumentum Enters into Global Licensing Agreement for a Novel Class of Investigational Pain Treatments

by Sky Striar | Oct 10, 2019 | In The Media, Press Releases

Agreement significantly expands Neumentum’s pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics  PALO ALTO, Calif., October 10, 2019 – Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain...

Neumentum Presents Data on Lead Product Candidate NTM-001 at PAINWeek 2019

by Sky Striar | Sep 5, 2019 | Press Releases

Neumentum’s poster presentations #39, #40, #41 and #42 from PAINWeek are now available to view.   – Results Support What Has the Potential To Be the First-Ever Non-Steroidal Anti-Inflammatory (NSAID) Approved for Continuous Infusion – Results Confirm...

Neumentum, Inc. Chief Executive Officer, Scott Shively, To Present at 2019 BIO International Convention in Philadelphia, PA

by admin | May 15, 2019 | In The Media, Press Releases

PALO ALTO, Calif., May 15, 2019 – Neumentum, a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer, will present at the 2019 BIO International Convention being held...

Neumentum Phase I Study Confirms Its Non-Opioid in Development for Moderately Severe Acute Pain, NTM-001, Performs in Healthy Adults as Predicted

by Sky Striar | Jan 7, 2019 | In The Media, Press Releases

– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...